[HTML][HTML] Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer …
N Yamamoto, T Seto, M Nishio, K Goto, I Okamoto… - Lung Cancer, 2021 - Elsevier
Abstract Objectives The JO25567 randomized Phase II study demonstrated a statistically
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …
Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib
B Melosky, J Agulnik, H Assi - Current Oncology, 2008 - mdpi.com
Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and
chemotherapy have both demonstrated efficacy in recurrent metastatic non-small-cell lung …
chemotherapy have both demonstrated efficacy in recurrent metastatic non-small-cell lung …
[HTML][HTML] Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang… - Annals of …, 2015 - Elsevier
Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
[HTML][HTML] Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib
K Tsujino, T Kawaguchi, A Kubo, N Aono… - Journal of thoracic …, 2009 - Elsevier
Introduction: Gaining a higher response rate (RR) has usually been determined as a primary
end point in phase II trials evaluating the efficacy of new molecular targeted drugs. However …
end point in phase II trials evaluating the efficacy of new molecular targeted drugs. However …
Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker
D Binder, AC Buckendahl, RH Hübner, P Schlattmann… - Medical Oncology, 2012 - Springer
Erlotinib is a relatively well-tolerated treatment option for patients with advanced non-small-
cell lung cancer (NSCLC). Some patients suffer from severe skin toxicity or diarrhea, making …
cell lung cancer (NSCLC). Some patients suffer from severe skin toxicity or diarrhea, making …
[HTML][HTML] Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer—the Holy Grail in cancer …
L Sellmann, K Fenchel… - Translational Lung Cancer …, 2015 - ncbi.nlm.nih.gov
Advanced or metastatic non-small-cell lung cancer (NSCLC) is characterized by a poor
prognosis and few second-or third-line treatments. First-generation epidermal growth factor …
prognosis and few second-or third-line treatments. First-generation epidermal growth factor …
[HTML][HTML] Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line …
Background In the placebo-controlled phase III SATURN study, maintenance erlotinib after
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
Experience with erlotinib in the treatment of non-small cell lung cancer
L Landi, F Cappuzzo - Therapeutic Advances in Respiratory …, 2015 - journals.sagepub.com
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths. In
the last decade, the epidermal growth factor receptor (EGFR) signalling pathway has …
the last decade, the epidermal growth factor receptor (EGFR) signalling pathway has …
Prospective study of gefitinib readministration after chemotherapy in patients with advanced non–small-cell lung cancer who previously responded to gefitinib
T Koizumi, T Agatsuma, K Ikegami, T Suzuki… - Clinical lung cancer, 2012 - Elsevier
Introduction Salvage treatment for acquired resistance to epidermal growth factor receptor
tyrosine kinase inhibitor in patients with non–small-cell lung cancer is a matter of clinical …
tyrosine kinase inhibitor in patients with non–small-cell lung cancer is a matter of clinical …
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer
F Cappuzzo, A Morabito, N Normanno, P Bidoli… - Lung Cancer, 2016 - Elsevier
Objectives Although patients with advanced non-small cell lung cancer (NSCLC) and an
activating epidermal growth factor receptor (EGFR) mutation benefit from the use of EGFR …
activating epidermal growth factor receptor (EGFR) mutation benefit from the use of EGFR …